StemRIM Inc. Logo

StemRIM Inc.

Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.

4599 | T

Overview

Corporate Details

ISIN(s):
JP3399690001
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ7丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

StemRIM Inc. is a biotechnology company engaged in the research and development of a next-generation class of regenerative medicine called "Regeneration-Inducing Medicine™". Originating as a venture from Osaka University, the company focuses on developing drugs with a novel mechanism of action. This approach aims to maximize the body's innate ability to repair itself by recruiting a patient's own in-vivo stem cells to damaged tissues, thereby inducing functional regeneration without conventional cell-therapy. The company's drug development pipelines target intractable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:38
Registration Form
有価証券届出書(参照方式)
Japanese 49.2 KB
2025-10-21 08:10
Registration Form
確認書
Japanese 8.1 KB
2025-10-21 08:10
Annual Report
有価証券報告書-第20期(2024/08/01-2025/07/31)
Japanese 2.7 MB
2025-09-12 05:32
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.7 KB
2025-03-13 04:31
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-03-13 04:30
Interim Report
半期報告書-第20期(2024/08/01-2025/07/31)
Japanese 228.6 KB
2024-11-25 08:13
Registration Form
有価証券届出書(参照方式)
Japanese 49.5 KB
2024-11-18 01:31
Share Issue/Capital Change
訂正臨時報告書
Japanese 32.6 KB
2024-11-13 08:10
Regulatory News Service
臨時報告書
Japanese 36.2 KB
2024-10-31 05:28
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-10-31 03:35
Governance Information
内部統制報告書-第19期(2023/08/01-2024/07/31)
Japanese 21.0 KB
2024-10-31 03:35
Registration Form
確認書
Japanese 8.1 KB
2024-10-31 03:32
Annual Report
有価証券報告書-第19期(2023/08/01-2024/07/31)
Japanese 2.7 MB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.7 KB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.8 KB

Automate Your Workflow. Get a real-time feed of all StemRIM Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for StemRIM Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for StemRIM Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SANGAMO THERAPEUTICS, INC Logo
Developing genomic cures for severe genetic diseases using proprietary zinc finger technology.
United States of America
SGMO
SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea
188260
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France
SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan
4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland
SANN
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK

Talk to a Data Expert

Have a question? We'll get back to you promptly.